Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

被引：8

作者：

Smit, E. F. ^{[1
]}

Felip, E. ^{[2
,3
]}

Uprety, D. ^{[4
]}

Nakagawa, K. ^{[5
]}

Paz-Ares, L. ^{[6
]}

Pacheco, J. ^{[7
,8
]}

Li, B. T. ^{[9
]}

Planchard, D. ^{[10
]}

Baik, C. ^{[11
]}

Goto, Y. ^{[12
]}

Murakami, H. ^{[13
]}

Saltos, A. ^{[14
]}

Saxena, K. ^{[15
]}

Shiga, R. ^{[16
]}

Cheng, Y. ^{[17
]}

Yan, Q. ^{[18
]}

Feng, W. ^{[19
]}

Janne, P. A. ^{[20
,21
]}

机构：

[1] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[2] Vall Hebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain

[3] Vall Hebron Inst Oncol, Barcelona, Spain

[4] Barbara Ann Karmanos Canc Inst, Med Oncol, Detroit, MI USA

[5] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan

[6] Univ Navarra, Dept Med Oncol, Univ Navarra Clin, Navarra, Spain

[7] Univ Colorado Anschutz, Internal Med, Aurora, CO USA

[8] Univ Colorado Anschutz, Div Med Oncol, Aurora, CO USA

[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[10] Gustave Roussy, Med Oncol, Thorac Team, Villejuif, France

[11] Univ Washington, Thorac Head & Neck Med Oncol, Seattle, WA USA

[12] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan

[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[14] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA

[15] Daiichi Sankyo Inc, R&D, Basking Ridge, NJ USA

[16] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA

[17] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA

[18] Daiichi Sankyo Inc, Biostat, Basking Ridge, NJ USA

[19] Daiichi Sankyo Inc, Global Compan Diagnost, Basking Ridge, NJ USA

[20] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

[21] Belfer Ctr Appl Canc Sci, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1103

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

975P

引用

页码：S994 / S995

页数：2

共 50 条

[41] Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non-small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)
Smit, E. F.
Felip, E.
Uprety, D.
Nagasaka, M.
Nakagawa, K.
Paz-Ares, L.
Pacheco, J.
Li, B. T.
Planchard, D.
Baik, C. S.
Goto, Y.
Murakami, H.
Pereira, K. M. C.
Taguchi, A.
Kogo, M.
Kuwahara, Y.
Zou, M.
Feng, W.
Tsuchihashi, Z.
Janne, P. A.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S241 - S242
[42] Influence of trastuzumab on the incidence of brain metastasis in patients with Her2-overexpressing metastatic breast cancer
Massard, C.
Brain, E.
Dunan, A.
Mathieu, M.
Guinebretiere, J.
Abuin, G. Gomez
Floiras, J.
Spielmann, M.
Delaloge, S.
Andre, F.
[J]. EJC SUPPLEMENTS, 2005, 3 (02): : 119 - 120
[43] HER2 copy number variation in non-small cell lung cancer (NSCLC)
Tagliamento, M.
Auclin, E.
Valent, A.
Ferrara, R.
Cotteret, S.
Rouleau, E.
Caramella, C.
Melia, M. Riudavets
Gazzah, A.
Adam, J.
Jovelet, C.
Bayle, A.
Lacroix, L.
Auger, N.
Barlesi, F.
Planchard, D.
Besse, B.
Mezquita, L.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1050 - S1050
[44] Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
Saura, C.
Modi, S.
Krop, I.
Park, Y. H.
Kim, S. -B.
Tamura, K.
Iwata, H.
Tsurutani, J.
Sohn, J.
Mathias, E.
Liu, Y.
Cathcart, J.
Singh, J.
Yamashita, T.
[J]. ANNALS OF ONCOLOGY, 2024, 35 (03) : 302 - 307
[45] High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) treated with trastuzumab and chemotherapy
Gori, S.
Rimondini, S.
De Angelis, V.
Sidoni, A.
Mosconi, A. M.
Aristei, C.
Franceschi, E.
Esposti, R. Degli
Colozza, M.
Crino, L.
[J]. EJC SUPPLEMENTS, 2005, 3 (02): : 115 - 116
[46] Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC)
Leyland-Jones, B
Marty, M
Baselga, J
Gatzemeier, U
Barton, C
Lennon, S
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 19S - 19S
[47] DESTINY-Breast01 trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer
Jackson, Emily B.
Simmons, Christine E.
Gelmon, Karen A.
[J]. TRANSLATIONAL BREAST CANCER RESEARCH, 2021, 2
[48] HER-2 Mutations in Non-Small Cell Lung Cancer
Sen, Erdem
Yavas, Guler
Ata, Ozlem
[J]. MEDICAL JOURNAL OF BAKIRKOY, 2018, 14 (03) : 322 - 325
[49] FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
Mehta, Gautam U.
Vellanki, Paz J.
Ren, Yi
Amatya, Anup K.
Mishra-Kalyani, Pallavi S.
Pan, Lili
Zirkelbach, Jeanne F.
Pan, Yuzhuo
Liu, Jiang
Aungst, Stephanie L.
Miller, Claudia P.
Shah, Mirat
Rahman, Nam Atiqur
Theoret, Marc
Kluetz, Paul
Pazdur, Richard
Beaver, Julia A.
Singh, Harpreet
[J]. ONCOLOGIST, 2024, 29 (08): : 667 - 671
[50] HER2 mutations in Chinese patients with non-small cell lung cancer
Song, Zhengbo
Yu, Xinmin
Shi, Zhiyong
Zhao, Jun
Zhang, Yiping
[J]. ONCOTARGET, 2016, 7 (47) : 78152 - 78158

← 1 2 3 4 5 →